Lebensqualität von Kinderlosen im Alter geringer: Verteilungen und Determinanten der Lebensqualität im Alter im internationalen Vergleich

'Die Alterung der Gesellschaft wird die Bedingungen des menschlichen Zusammenlebens grundlegend ändern. Auch werden alternde Gesellschaften neue, zum Teil noch gar nicht absehbare, politische und wirtschaftliche Herausforderungen zu bestehen haben: 'Alter' und 'Altern' gelten als ein gesellschaftliches Zukunftsthema und geraten zunehmend in das Blickfeld der wissenschaftlichen und politischen Öffentlichkeit. Vor allem das höhere Lebensalter hat sich als eine eigenständige Lebensphase herausgebildet - gekennzeichnet einerseits durch neue biographische Entwürfe und Formen sozialer Beteiligung, andererseits aber auch geprägt durch Krankheit, Hilfebedürftigkeit und Tod. Mit der Verlängerung der Lebenserwartung bekommt auch die Frage nach den Bedingungen und Möglichkeiten, unter denen Autonomie und Lebensqualität im höheren Lebensalter aufrechterhalten werden, eine neue Bedeutung. Dabei ist auch über Zielgrößen, nicht zuletzt vom Autor dieses Beitrags zu diskutieren: Lebensqualität muss als Maß des Erfolgs sozialpolitischer Intervention verstanden und thematisiert werden, und zwar vor dem Hintergrund der Frage nach der Finanzierbarkeit sozialstaatlicher Leistungen und der Effizienz verschiedener Alternativen.' (Autorenreferat

Second International Consensus Conference on Advanced Breast Cancer (ABC2), Lisbon, 11/09/2013: The German Perspective

The Advanced Breast Cancer Second International Consensus Conference (ABC2) on diagnosis and treatment of advanced breast cancer took place in Lisbon, Portugal, on November 7-9, 2013. The focus of the conference was inoperable, locally advanced breast cancer. The diagnosis and treatment of metastatic breast cancer had already been discussed 2 years before at the ABC1 Consensus and were only updated regarding special issues as part of this year's ABC2 Consensus. Like 2 years ago, a working group of German breast cancer experts commented on the voting results of the ABC panelists, with special consideration of the German guidelines for the diagnosis and treatment of breast cancer (German Gynecological Oncology Working Group (AGO) recommendations, S3 Guideline) in order to adapt them for daily clinical practice in Germany. The goal of both the ABC Consensus and the German comments is to facilitate evidence-based therapy decisions

Update breast cancer 2021 part 5 – advanced breast cancer

Despite the COVID 19 pandemic and mostly virtual congresses, innovation in the treatment of breast cancer patients continues at an unabated pace. This review summarises the current developments. Initial overall survival data for CDK4/6 inhibitor treatment in combination with an aromatase inhibitor as the first advanced line of therapy in treatment-naive postmenopausal patients have been published. Similarly, a trial comparing trastuzumab-deruxtecan versus trastuzumab-emtansine revealed a clear benefit regarding progression-free survival. Understanding of biomarkers making checkpoint inhibitor therapy particularly effective is increasing, and new compounds such as oral selective estrogen receptor destabilisers (SERDs) are entering clinical development and completing the first phase III trials

Update breast cancer 2021 part 4 – prevention and early stages

This past year has seen new and effective options for further improving treatment outcome in many patients with early-stage breast cancer. Patients with hormone receptor-positive disease benefited significantly from the addition of the CDK4/6 inhibitor abemaciclib to endocrine adjuvant therapy. In triple-negative disease, data were presented for two treatment regimens. Patients with advanced disease (stage 2 and 3) benefit from neoadjuvant treatment with the immune checkpoint inhibitor pembrolizumab in combination with standard chemotherapy, regardless of PD-L1 expression. When neoadjuvant therapy has failed to achieve the desired remission in BRCA1 and BRCA2 mutations, the administration of the PARP inhibitor olaparib has demonstrated an impressive response. Other data address translational issues in HER2-positive breast cancer and neoadjuvant therapy approaches with the oral SERD giredestrant and the PARP inhibitor talazoparib. This review presents and analyses the findings of this yearʼ s most important study outcomes

Update breast cancer 2022 part 4 – advanced-stage breast cancer

For the treatment of patients with advanced HER2-negative hormone receptor-positive breast cancer, several substances have been introduced into practice in recent years. In addition, other drugs are under development. A number of studies have been published over the past year which have shown either an advantage for progression-free survival or for overall survival. This review summarizes the latest results, which have been published at current congresses or in specialist journals, and classifies them in the clinical treatment context. In particular, the importance of therapy with CDK4/6 inhibitors – trastuzumab deruxtecan, sacituzumab govitecan and capivasertib – is discussed. For trastuzumab deruxtecan, an overall survival benefit in HER2-negative breast cancer with low HER2 expression (HER2-low expression) was reported in the Destiny-Breast-04 study. Similarly, there was an overall survival benefit in the FAKTION study with capivasertib. The lack of overall survival benefit for palbociclib in the first line of therapy raises the question of clinical classification